menu
    • menu

    Company profile for Radionetics Oncology

    NEW Drugs in Dev: 3
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide tec...
    Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company’s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein-targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Radionetics OncologyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    San Diego, CA 92121
    Telephone
    Telephone
    +1 8582186617
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://radionetics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/radionetics-oncology/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    The Rise of GPCRs, Radiopharma & Peptide Screening
    The Rise of GPCRs, Radiopharma & Peptide Screening

    14 May 2026

    // BIOSPACE

    https://www.biospace.com/drug-development/gpcrs-radiopharma-and-the-rise-of-functional-peptide-screening

    BIOSPACE
    14 May 2026
    Share Share
    Radionetics Oncology, GordonMD Portfolio Company, Partners With Lilly
    Radionetics Oncology, GordonMD Portfolio Company, Partners With Lilly

    08 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240708644984/en

    BUSINESSWIRE
    08 Jul 2024
    Share Share
    Radionetics Oncology Enters Into Strategic Agreement With Lilly
    Radionetics Oncology Enters Into Strategic Agreement With Lilly

    02 Jul 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240628237510/en/Radionetics-Oncology-Enters-Into-Strategic-Agreement-With-Lilly

    BUSINESSWIRE
    02 Jul 2024
    Share Share
    Lilly signs $140M upfront partnership with Radionetics in radiopharma play
    Lilly signs $140M upfront partnership with Radionetics in radiopharma play

    01 Jul 2024

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/lilly-signs-140m-upfront-partnership-radionectics-latest-radiopharma-play

    FIERCE BIOTECH
    01 Jul 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search